China Resources Sanjiu Medical & Pharmaceutical Co (000999) Q3 2026 earnings summary

Executive summary

• Q3 revenue was ¥6.396bn; YTD revenue reached ¥21.410bn, down 2.62% YoY. YTD net income attributable to shareholders was ¥2.158bn, down 8.30%.

• YTD adjusted net income was ¥2.066bn, down 5.48%; adjusted Q3 net income was ¥469.5m, down 3.90%.

Financial highlights

• Q3 net income attributable to shareholders was ¥486.9m, down 10.87% YoY; Q3 adjusted net income was ¥469.5m, down 3.90%.

• YTD operating cash flow was ¥2.297bn, down 21.47% YoY.

• YTD other income fell 37.12% to ¥149.9m, primarily reflecting lower government grants.

Key financial ratios and metrics

• Basic and diluted EPS were ¥0.29 for Q3, down 9.38% YoY, and ¥1.30 YTD, down 8.45%.

• Total assets were ¥55.437bn at quarter-end, down 5.73% from year-end; shareholder equity attributable to the parent was ¥22.625bn, up 2.04%.